© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Rethinking Supplemental Oxygen: Physicians, Patients, and Caregivers Weigh In
May 21st 2019
DALLAS--Supplemental oxygen helps patients with lung disease manage better day-to-day, but according to speakers gathered at the ATS meeting in Dallas this week, it can also add to disease burden.
A Pro-Con Debate on How to Care for Patients With Interstitial Lung Disease
May 21st 2019
DALLAS--Which patients are candidates for antifibrotic therapy? Is extracorporeal membrane oxygenation appropriate for all ILD patients? The topics were hotly debated on Monday at the American Thoracic Society meeting.
Type 2 Diabetes: Clinical Suspicion and Diagnosis
May 8th 2019
Who is at risk for T2DM? How often should you screen? What are the cut offs for Dx? Revisit the basics in 5 minutes or less.
A Non-smoker with Progressive Dyspnea, No Cough
January 1st 2018
Dorothy is 55-years-old, has never smoked, and was well until 1 year ago when she first noticed mild dyspnea on exertion; it has gotten progressively worse.
COPD Exacerbations: Frequently Asked Questions
January 1st 2018
A pulmonologist answers some of the most common questions he hears from colleagues and students about COPD exacerbations and their management.
A Primary Care Approach to Interstitial Lung Disease
November 27th 2017
A pulmonologist describes an approach to guide the primary care clinician faced with a patient in whom interstitial lung disease is suspected.
Treatment Strategies to Limit Hypoglycemia
June 16th 2017
Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.
ADA 2017: Hypoglycemia and the Role of Glycemic Variability
June 15th 2017
Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.
ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
June 14th 2017
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.